EcoDrugPlus

Neuropeptide Y Receptor Y4

Ensembl ID : ENSNBRG00000011977
Gene Symbol: NPY4R
1 Cross references
135 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSNBRG00000000287
Gene Symbol: LOC102791934
3 Cross references
176 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSNBRG00000020181
Gene Symbol: NTSR1
3 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSNBRG00000011797
Gene Symbol: NTRK2
1 Cross references
206 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSNBRG00000006614
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSNBRG00000011960
Gene Symbol: NTRK3
4 Cross references
202 Possible Orthologues:

Nicastrin

Ensembl ID : ENSNBRG00000016410
Gene Symbol: NCSTN
4 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSNBRG00000001688
Gene Symbol: NAMPT
3 Cross references
225 Possible Orthologues:

Nociceptin Receptor-Like

Ensembl ID : ENSNBRG00000008529
Gene Symbol: LOC102790530
3 Cross references
189 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSNBRG00000011018
Gene Symbol: LOC102790932
3 Cross references
216 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSNBRG00000013462
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSNBRG00000005976
Gene Symbol: NR3C1
4 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).